Libertyville, IL, United States of America

Regina M Reilly

This inventor holds 1 USPTO granted patent and 7 published patent applications and 1 EPO patent. Top assignee: Abbvie Inc.. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Regina M Reilly. Retrieved from https://idiyas.com/inventor/regina-m-reilly

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Regina M Reilly: Innovator in Antibody Drug Conjugates

Introduction

Regina M Reilly is a notable inventor based in Libertyville, IL (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibody drug conjugates. Her work has the potential to advance cancer treatment and improve patient outcomes.

Latest Patents

Regina M Reilly holds 1 patent for her invention titled "Anti-c-Met antibody drug conjugates." This patent provides compositions and methods for using c-Met antibody drug conjugates (ADCs), which are designed to target and treat specific cancer cells effectively.

Career Highlights

Throughout her career, Regina has worked with prominent companies in the pharmaceutical industry. She has been associated with AbbVie Inc. and AbbVie Manufacturing Management Unlimited Company, where she has contributed her expertise in drug development and innovation.

Collaborations

Regina has collaborated with esteemed colleagues, including Andrew C Phillips and George A Doherty. These partnerships have fostered a collaborative environment that enhances research and development efforts in the field.

Conclusion

Regina M Reilly's innovative work in antibody drug conjugates exemplifies her commitment to advancing medical science. Her contributions are paving the way for new therapeutic options in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…